IGF-1 DES Nasal Spray

IGF-1 DES is des(1-3)IGF-1: the human IGF-1 sequence without its N-terminal Gly-Pro-Glu, 67 residues folded around three disulfides. This listing supplies it as a sterile solution in bacteriostatic water in a metered nasal spray bottle; the label gives the amount and concentration. Research on the truncated protein covers its binding-protein behaviour and potency in cells and rats, and the removed tripeptide has been studied separately in brain tissue.

Specifications

What is in the bottle

The bottle holds IGF-1 DES dissolved in bacteriostatic water with 0.9% benzyl alcohol. Its amount and concentration are printed on the label; the safety data sheet records them only as labelled, under 10% w/v. Benzyl alcohol is the hazardous component, harmful if swallowed or inhaled, irritating to the eyes and able to sensitise skin, and the protein itself is not classified. Store the bottle upright with its cap on at 2 to 8 °C, shielded from light and never frozen. When a laboratory needs a stated mass of protein to work from, the IGF-DES 2 mg vial supplies it freeze-dried; peptide storage and stability covers solutions in general.

What the research covers

Removing Gly-Pro-Glu from IGF-1 changes how the protein meets the IGF-binding proteins more than how it meets its receptor. Bagley and colleagues compared IGF-1 with versions truncated by one to five residues and found des(1-3) the most potent in L6 myoblasts, with receptor competition at 3 °C close to that of IGF-1¹. A binding protein secreted by the myoblasts recognised the three longest peptides at least 60-fold better than the shorter ones, which accounted for the gain in potency¹. Binding proteins of this kind sequester IGFs away from the type I IGF receptor, though proteolysis or association with cells and matrix can change that².

The missing tripeptide has its own literature. Sara and colleagues reported a truncated IGF-1 lacking GPE in human brain; GPE made synthetically blocked glutamate binding at NMDA receptors and strongly increased potassium-evoked acetylcholine release in slices of rat cortex³. That work concerns GPE, which this product does not contain, and none of the references studied IGF-1 DES delivered through the nose. The IGF-1 LR3 guide compares the IGF-1 analogues in more depth.

How each lot is tested

Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. Published certificates are listed on the results page and can be checked by number and key on the verify page. The certificate covers the peptide lot used to fill the bottle, not the finished solution. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.

Frequently asked questions

References

1. Bagley CJ, May BL, Szabo L, et al. A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide. Biochem J. 1989;259(3):665-71. DOI · PubMed
2. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824-54. DOI · PubMed
3. Sara VR, Carlsson-Skwirut C, Bergman T, et al. Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide. Biochem Biophys Res Commun. 1989;165(2):766-71. DOI · PubMed